Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy

Trial Profile

A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif) in Patients With Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms CARE-MS-II
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 12 Oct 2018 Results of pooled analysis of CARE-MS I (NCT00530348) and II (NCT00548405) 6 year follow up trials, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
    • 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 12 Oct 2018 Results examining the impact of thyroid adverse effects over 6 years on multiple domains of QoL in pooled CARE-MS I/II (CARE-MS I and II; NCT00530348; NCT00548405 and in a 4-year extension (NCT00930553)) , patients presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top